{"id":"https://openalex.org/W85655972","doi":null,"title":"Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.","display_name":"Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.","publication_year":2006,"publication_date":"2006-09-01","ids":{"openalex":"https://openalex.org/W85655972","mag":"85655972","pmid":"https://pubmed.ncbi.nlm.nih.gov/16952072"},"language":"en","primary_location":{"id":"pmid:16952072","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16952072","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Clinical Trial, Phase II"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039497051","display_name":"Laurie M. Elit","orcid":"https://orcid.org/0000-0001-8966-1937","observed_orcids":["https://orcid.org/0000-0001-8966-1937"]},"institutions":[{"id":"https://openalex.org/I2799698466","display_name":"Juravinski Cancer Centre","ror":"https://ror.org/02cwjh447","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2799698466","https://openalex.org/I76442945"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Laurie Elit","raw_affiliation_strings":["Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada, laurie.elit@hrcc.on.ca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada, laurie.elit@hrcc.on.ca","institution_ids":["https://openalex.org/I2799698466"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5039497051"],"corresponding_institution_ids":["https://openalex.org/I2799698466"],"apc_list":null,"apc_paid":null,"fwci":0.5614,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.56711901,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"9","issue":"9","first_page":"636","last_page":"44"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12049","display_name":"Tuberous Sclerosis Complex Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.7210000157356262},{"id":"https://openalex.org/keywords/rapamycin-analogues","display_name":"rapamycin analogs","score":0.9729999899864197},{"id":"https://openalex.org/keywords/cancer-therapy","display_name":"cancer therapy","score":0.6729999780654907},{"id":"https://openalex.org/keywords/vascular-smooth-muscle-cells","display_name":"vascular smooth muscle cells","score":0.8489999771118164},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.6650000214576721},{"id":"https://openalex.org/keywords/cell-migration","display_name":"cell migration","score":0.7390000224113464},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.75},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.8140000104904175},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.8266646862030029},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.7803443670272827},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6014024615287781},{"id":"https://openalex.org/C2777921159","wikidata":"https://www.wikidata.org/wiki/Q32089","display_name":"Sirolimus","level":2,"score":0.5957736968994141},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5270640850067139},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5207288861274719},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4321158230304718},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.392203152179718},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3288307785987854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20681127905845642},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.1426856815814972},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09772038459777832}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:16952072","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16952072","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Clinical Trial, Phase II"},{"id":"mag:85655972","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16952072","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2275499694","https://openalex.org/W2277470516","https://openalex.org/W2403500327","https://openalex.org/W2143393758","https://openalex.org/W7098249464","https://openalex.org/W2532819729","https://openalex.org/W1426517451","https://openalex.org/W2017389272","https://openalex.org/W2040182003","https://openalex.org/W2052092291"],"abstract_inverted_index":{"ARIAD":[0],"Pharmaceuticals":[1],"Inc":[2],"is":[3],"developing":[4],"intravenous":[5],"and":[6,14,26,41],"oral":[7],"formulations":[8],"of":[9,16,20,28,37],"AP-23573,":[10],"a":[11],"rapamycin":[12],"analog":[13],"inhibitor":[15],"mTOR":[17],"(mammalian":[18],"target":[19],"rapamycin)":[21],"that":[22],"blocks":[23],"the":[24,34],"proliferation":[25],"migration":[27],"vascular":[29],"smooth":[30],"muscle":[31],"cells,":[32],"for":[33],"potential":[35],"treatment":[36],"cancer,":[38],"including":[39],"solid":[40],"hematological":[42],"forms.":[43]},"counts_by_year":[{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}